

24 March 2026

Endometrial Cancer

1. Does your trust provide SACT (systemic anti-cancer therapy) treatments for endometrial cancer? If not, which other trust do you refer endometrial cancer patients to for SACT treatments?

Yes.

2. How many patients were treated for endometrial cancer (any stage) in the past three months with the following treatments:

- Dostarlimab (Jemperli) : <5
- Dostarlimab (Jemperli) + Chemotherapy: 5
- Hormone therapy (Progesterone or Letrozole): 0
- Lenvatinib + Pembrolizumab (Keytruda + Lenvima): 0
- Pembrolizumab monotherapy (Keytruda): 0
- Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide): 32
- Durvalumab with Platinum-based Chemotherapy: 0
- Pembrolizumab with Platinum-based Chemotherapy: <5
- Any other SACT: Paclitaxel <5, Carboplatin+XRT <5
- If the Trust are using Pembrolizumab subcutaneous injection, please can you provide the number of patients who received treatment with Pembrolizumab subcutaneous injection with Platinum-based Chemotherapy for Endometrial cancer: 0

3. In the past three months, how many patients were treated for endometrial cancer with the following as first line treatments:

- Dostarlimab (Jemperli) + Chemotherapy: 0
- Hormone therapy (Progesterone or Letrozole): 0
- Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide): 12
- Durvalumab with Platinum-based Chemotherapy: 0
- Pembrolizumab with Platinum-based Chemotherapy: <5
- Any other SACT: Carboplatin+XRT <5
- If the Trust are using Pembrolizumab subcutaneous injection, please can you provide the number of patients who received treatment with Pembrolizumab subcutaneous injection with Platinum-based Chemotherapy for first line Endometrial cancer: 0

24 March 2026

- 4. Does your trust participate in any clinical trials for the treatment of endometrial cancer? If so, can you please provide the name of each trial and the number of patients taking part.**

None at present.

Where numbers are low we have put <5 rather than state the actual figure. To ensure that patient remain non identifiable. Disclosure of this information would breach the first data protection principle, which relates to the fair and lawful processing of personal data. Therefore, we have concluded that this information is exempt from disclosure under Section 40(2) of the Freedom of Information Act - Personal Information relating to a third party.